- Sweden
- /
- Medical Equipment
- /
- OM:BACTI B
Further weakness as Bactiguard Holding (STO:BACTI B) drops 11% this week, taking three-year losses to 78%
As an investor, mistakes are inevitable. But you have a problem if you face massive losses more than once in a while. So consider, for a moment, the misfortune of Bactiguard Holding AB (publ) (STO:BACTI B) investors who have held the stock for three years as it declined a whopping 78%. That would be a disturbing experience. The more recent news is of little comfort, with the share price down 58% in a year. Furthermore, it's down 24% in about a quarter. That's not much fun for holders.
After losing 11% this past week, it's worth investigating the company's fundamentals to see what we can infer from past performance.
See our latest analysis for Bactiguard Holding
Bactiguard Holding wasn't profitable in the last twelve months, it is unlikely we'll see a strong correlation between its share price and its earnings per share (EPS). Arguably revenue is our next best option. Generally speaking, companies without profits are expected to grow revenue every year, and at a good clip. That's because fast revenue growth can be easily extrapolated to forecast profits, often of considerable size.
In the last three years, Bactiguard Holding saw its revenue grow by 4.6% per year, compound. Given it's losing money in pursuit of growth, we are not really impressed with that. Nonetheless, it's fair to say the rapidly declining share price (down 21%, compound, over three years) suggests the market is very disappointed with this level of growth. While we're definitely wary of the stock, after that kind of performance, it could be an over-reaction. Of course, revenue growth is nice but generally speaking the lower the profits, the riskier the business - and this business isn't making steady profits.
You can see how earnings and revenue have changed over time in the image below (click on the chart to see the exact values).
We consider it positive that insiders have made significant purchases in the last year. Having said that, most people consider earnings and revenue growth trends to be a more meaningful guide to the business. So it makes a lot of sense to check out what analysts think Bactiguard Holding will earn in the future (free profit forecasts).
A Different Perspective
Investors in Bactiguard Holding had a tough year, with a total loss of 58%, against a market gain of about 16%. However, keep in mind that even the best stocks will sometimes underperform the market over a twelve month period. Regrettably, last year's performance caps off a bad run, with the shareholders facing a total loss of 10% per year over five years. We realise that Baron Rothschild has said investors should "buy when there is blood on the streets", but we caution that investors should first be sure they are buying a high quality business. While it is well worth considering the different impacts that market conditions can have on the share price, there are other factors that are even more important. Case in point: We've spotted 2 warning signs for Bactiguard Holding you should be aware of.
There are plenty of other companies that have insiders buying up shares. You probably do not want to miss this free list of undervalued small cap companies that insiders are buying.
Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on Swedish exchanges.
Valuation is complex, but we're here to simplify it.
Discover if Bactiguard Holding might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.
Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
About OM:BACTI B
Bactiguard Holding
A medical device company, provides infection prevention solutions in orthopedics, urology, intravascular/critical care, dental, and wound care therapeutic areas in the United States, Sweden, Malaysia, India, Bangladesh, Indonesia, the Kingdom of Saudi Arabia, and internationally.
Good value with reasonable growth potential.